Federal Circuit Dramatically Narrows Scope of Proper Venue in Paragraph IV Litigation
Valeant v. Mylan, No. 19-2402 (Fed. Cir.) by Alex Menchaca In a precedential decision last week, the Federal Circuit settled how the Supreme
Tag : Paragraph Iv Cases
Split Federal Circuit Panel Reinstates Jury Verdict of Induced Infringement in Coreg (carvedilol) Case
GlaxoSmithKline v. Teva, No. 18-1976 (Fed. Cir. 2020) by Alex Menchaca In our last post, we reported that Chief Judge Stark of the District
Judge Stark (D. Del.) Holds Generic Label Including Patented Indication is Insufficient to Prove Inducement
GlaxoSmithKline v. Teva, No. 14-878-LPS-CJB (D. Del.) by Aaron F. Barkoff In an opinion last week, Judge Stark of the District of Delaware
Federal Circuit Holds That Specific Personal Jurisdiction Exists Anywhere an ANDA Applicant Intends to Market its ANDA Product
Acorda Therapeutics v. Mylan Pharms., 2015-1456 (Fed. Cir. March 18, 2016) AstraZeneca v. Mylan Pharms, 2015-1460 (Fed. Cir. March 18, 2016) by
Case or Controversy Exists Where Generic Manufacturer Seeks Declaratory Judgment of Non-Infringement of Orange Book-Listed Patent Disclaimed by Brand Manufacturer
Apotex Inc. v. Daiichi Sankyo, Inc., Nos. 2014-1282, 2014-1291 (Fed. Cir. Mar. 31, 2015) by Dunstan H. Barnes Apotex, Inc. sued Daiichi Sankyo
Federal Circuit Revives Mutual's Antitrust Counterclaims Arising From Temazepam ANDA Litigation
Tyco Healthcare et al. v. Mutual Pharm. et al., No. 2013-1386 (Fed. Cir.) by Aaron F. Barkoff In 2006, Mutual filed an ANDA for a generic
District of New Jersey Allows ANDA Filer's Declaratory Judgment Action to Proceed Despite Covenant Not to Sue
Purdue Pharm. Products v. TWI Pharms., No. 12-5311 (D.N.J.) by Alex Menchaca In an opinion last week, the U.S. District Court for the
Federal Circuit Affirms Validity of Pfizer's Lyrica (Pregabalin) Patent
Pfizer Inc. et al. v. Teva Pharms. USA et al., No. 2012-1576 (Fed. Cir.) Teva and several other generic pharmaceutical companies each submitted an
PTAB Institutes Inter Partes Review of Oracea (doxycycline) Formulation Patents
Amneal Pharmaceuticals, LLC v. Supernus Pharmaceuticals, Inc., IPR2013-00368, IPR2013-00371, IPR2013-00372 (PTAB) by Robert F. Kappers The
Divided Federal Circuit Panel Strikes Down Galderma’s Patents as Obvious—in Shifting the Burden of Production Regarding Secondary Considerations to the Patentee, Did the Majority in Fact Shift the Burden of Persuasion, Too?
Galderma Labs., L.P. et al. v. Tolmar, Inc., No. 2013-1034 (Fed. Cir.) by Dunstan H. Barnes On December 11, 2013, a three-judge Federal Circuit
Cadence Prevails Over Exela in OFIRMEV® (Acetaminophen) ANDA Litigation
Cadence Pharms., Inc. v. Exela Scis., LLC, No. 11-733-LPS (D. Del.) by Dunstan H. Barnes On November 22, 2013, the U.S. District Court for the
Motion to Amend Pleadings to Assert Inequitable Conduct Denied in Rapamycin Case
Pfizer Inc. v. Sandoz Inc., No. 12-654-GMS-MPT (D. Del.) by Malaika D. Tyson Undue delay that resulted in prejudice to Pfizer coupled with
Invalidity Due to Public Use in ANDA Cases
Pronova Biopharma Norge v. Teva Pharms., No. 2012-1498 (Fed. Cir.) by Aaron F. Barkoff It is not unusual for a defendant in an ANDA case to
Invalidity Due to Prior Public Use in ANDA Cases
Pronova Biopharma Norge v. Teva Pharms., No. 2012-1498 (Fed. Cir.) by Aaron F. Barkoff It is not unusual for a defendant in an ANDA case to
Federal Circuit Affirms Obviousness of Novo Nordisk's PRANDIN Patent
Novo Nordisk v. Caraco Pharm. Labs., No. 2011-1223 (Fed. Cir.) by Timothy M. Long In its third trip to the Federal Circuit, the court on